Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Merck KGaA is a Germany-based science and technology company. The Company operates in three business segments: Healthcare, Life Sciences and Electronics. The Healthcare business, which operates in the United States and Canada as EMD Serono, focuses on such therapeutic areas as allergies, fertility, oncology and neurodegenerative diseases, developing drugs, diagnostic substances and medical devices. The Life Sciences business comprises the activities of MilliporeSigma, which provides solutions that facilitate biotechnology and pharmaceutical research. The product range includes laboratory water systems, gene editing tools, cell lines and end-to-end drug manufacturing systems, among others. The Electronics business enables digital living and provides specialty chemicals for various applications, including liquid crystals for electronic displays, materials for integrated circuits, effect pigments for coatings and color cosmetics, as well as functional materials for energy solutions.

  • Revenue in USD (TTM)24.11bn
  • Net income in USD3.61bn
  • Incorporated1995
  • Employees64.23k
  • Location
    Merck KGaAFrankfurter Str. 250DARMSTADT 64293GermanyDEU
  • Phone+49 6151720
  • Fax+49 6 151722000
  • Websitehttps://www.emdgroup.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Exact Sciences Corp2.08bn-623.51m11.96bn6.30k--3.92--5.74-3.54-3.5411.8217.100.32295.1511.13330,837.90-9.66-12.12-10.41-13.2972.4474.21-29.91-36.432.09-14.790.4247--17.9550.94-4.68--25.37--
Sarepta Therapeutics Inc933.01m-703.49m12.01bn1.16k--31.20--12.88-8.03-8.0310.664.380.29730.71765.08802,937.20-22.42-23.30-27.04-27.1185.0086.31-75.40-96.383.80-17.840.8005--32.9343.27-67.99--7.76--
Catalent Inc4.76bn409.00m12.05bn19.00k29.612.4514.882.532.262.2626.2827.290.44564.133.67250,368.403.844.594.375.2132.7132.748.629.401.364.430.4970.0020.7618.39-4.9135.5836.40--
Incyte Corporation3.39bn340.66m15.86bn2.32k46.753.6338.834.671.521.5215.1619.620.63015.315.381,460,686.006.328.327.7810.0394.5495.4910.0411.843.506.640.00760.0013.6717.18-64.09---6.86--
ICON PLC7.74bn505.30m17.21bn41.10k34.372.0315.962.226.136.1393.87103.980.4478--3.33188,354.902.944.743.465.9028.6628.756.577.92--3.810.3539--41.2434.50229.8711.7726.03--
Biomarin Pharmaceutical Inc2.10bn141.56m17.57bn3.08k129.003.8172.158.380.73020.730211.1224.710.33870.5795.02680,090.502.29-0.08662.52-0.098576.9276.076.75-0.25493.15--0.1908--13.539.80308.18---7.97--
Merck KGaA (ADR)24.11bn3.61bn23.71bn64.23k22.122.884.260.98361.661.6611.0812.930.47362.005.49375,299.907.11--9.05--61.6562.6115.0211.920.795726.910.28569.6412.938.908.875.47----
Alnylam Pharmaceuticals, Inc.1.04bn-1.13bn24.32bn2.00k------23.44-9.30-9.308.53-1.280.28861.576.27518,190.80-31.47-32.56-39.51-38.9883.7384.49-109.04-168.243.34-3.031.18--22.8863.09-32.64---7.11--
Horizon Therapeutics PLC3.63bn521.48m24.88bn2.12k49.114.8827.286.852.222.2215.4322.320.40794.665.541,715,860.005.866.526.547.5574.6474.0514.3716.803.678.790.33570.0012.4828.00-2.43--71.34--
Gartner Inc5.48bn807.80m25.17bn19.50k31.89110.6525.184.609.989.9867.572.880.7442--3.70280,812.6010.986.2720.8710.8969.0766.7014.759.85--9.590.9153--15.6710.581.79---0.4951--
DuPont de Nemours Inc13.02bn1.01bn32.46bn23.00k35.201.2214.782.492.0112.0926.0658.000.2993.815.57565,956.502.440.21932.740.288935.4534.768.151.442.405.800.2301840.003.592.21-12.68---27.682.98
Data as of Mar 30 2023. Currency figures normalised to Merck KGaA's reporting currency: US Dollar USD

Institutional shareholders

0.02%Per cent of shares held by top holders
HolderShares% Held
Henry James International Management, Inc.as of 31 Dec 202284.70k0.01%
Envestnet Asset Management, Inc.as of 30 Nov 202234.62k0.01%
Yousif Capital Management LLCas of 31 Dec 202210.80k0.00%
Lazard Asset Management LLCas of 28 Feb 20238.85k0.00%
Yorktown Management & Research Co., Inc.as of 28 Feb 20238.45k0.00%
SYSTM Wealth Solutions LLCas of 31 Dec 20226.70k0.00%
PNC Investments LLCas of 31 Dec 20222.31k0.00%
RAM Active Investments SAas of 30 Jun 20221.80k0.00%
Thomas White International Ltd.as of 31 Dec 20221.27k0.00%
First Horizon Advisors, Inc.as of 31 Dec 2022277.000.00%
More ▼
Data from 30 Jun 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.